EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex.

Nucleic Acids Research
Saravana P SelvanathanJeffrey A Toretsky

Abstract

Connections between epigenetic reprogramming and transcription or splicing create novel mechanistic networks that can be targeted with tailored therapies. Multiple subunits of the chromatin remodeling BAF complex, including ARID1A, play a role in oncogenesis, either as tumor suppressors or oncogenes. Recent work demonstrated that EWS-FLI1, the oncogenic driver of Ewing sarcoma (ES), plays a role in chromatin regulation through interactions with the BAF complex. However, the specific BAF subunits that interact with EWS-FLI1 and the precise role of the BAF complex in ES oncogenesis remain unknown. In addition to regulating transcription, EWS-FLI1 also alters the splicing of many mRNA isoforms, but the role of splicing modulation in ES oncogenesis is not well understood. We have identified a direct connection between the EWS-FLI1 protein and ARID1A isoform protein variant ARID1A-L. We demonstrate here that ARID1A-L is critical for ES maintenance and supports oncogenic transformation. We further report a novel feed-forward cycle in which EWS-FLI1 leads to preferential splicing of ARID1A-L, promoting ES growth, and ARID1A-L reciprocally promotes EWS-FLI1 protein stability. Dissecting this interaction may lead to improved cancer-spec...Continue Reading

References

May 29, 2000·The Journal of Biological Chemistry·L L Knoop, S J Baker
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·C W RobertsS H Orkin
Sep 20, 2005·Genome Biology·Stephen R HendersonChris Boshoff
Oct 19, 2005·Cancer Research·Kristin BairdPaul S Meltzer
Mar 16, 2006·Molecular and Cellular Biology·Sungeun KimRon Wisdom
May 8, 2007·Cancer Cell·Franck TirodeOlivier Delattre
Feb 26, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karl-Ludwig SchaeferChristopher Poremba
Jun 3, 2009·Biochemical and Biophysical Research Communications·Capucine Van RechemDominique Leprince
Aug 14, 2009·Molecular Carcinogenesis·Jessica DelBoveBernard E Weissman
Oct 30, 2010·Cell·J Robert Hogg, Stephen P Goff
Nov 3, 2010·Genes & Development·Charles J David, James L Manley
Jan 11, 2011·Cell·Reini F LucoTom Misteli
Mar 25, 2011·Methods in Molecular Biology·Mona BatishSanjay Tyagi
Feb 14, 2012·Nature Genetics·Sophie Postel-VinayOlivier Delattre
Mar 3, 2012·Oncotarget·Julie S Barber-RotenbergJeffrey A Toretsky
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg
Mar 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Mona BatishSanjay Tyagi
Sep 1, 2012·Human Molecular Genetics·Seth J BrownYi Xing
Feb 25, 2014·Nature Medicine·Katherine C HelmingCharles W M Roberts
Mar 29, 2014·PloS One·Fatu Badiane MarkeyMona Batish
Sep 3, 2014·The Journal of Cell Biology·Jeffrey A Toretsky, Peter E Wright
Sep 5, 2014·Cancer Discovery·Brian D CromptonKimberly Stegmaier
Mar 5, 2015·Proceedings of the National Academy of Sciences of the United States of America·Saravana P SelvanathanJeffrey A Toretsky
Jul 15, 2016·Cold Spring Harbor Perspectives in Medicine·Courtney HodgesGerald R Crabtree
Dec 13, 2016·Nature Genetics·Benjamin Z StantonGerald R Crabtree
Dec 13, 2016·Nature Genetics·Radhika MathurCharles W M Roberts
Aug 29, 2017·Cell·Gaylor BoulayMiguel N Rivera
Dec 23, 2017·Molecular Cell·Thomas VierbuchenMichael E Greenberg
Jan 29, 2018·Cancer Letters·Ophelie ArnaudFranck Tirode
Apr 10, 2019·EMBO Reports·Malin LindénPierre Åman

❮ Previous
Next ❯

Citations

Sep 26, 2020·Frontiers in Genetics·Jian ZhangCheng-Guo Duan
May 8, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Liangchen Qu Youyou Zhu
May 27, 2021·RNA·Nasiha S AhmedJacob C Schwartz
Jul 24, 2021·Scientific Reports·Hongshuai LiNan Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-Seq
caspase assay
co-immunoprecipitation
Co-IP
PCR
ELISA
exome sequencing
RNAseq
transfection
CoIP

Clinical Trials Mentioned

NCT02657005
NCT00070109
NCT03600649
NCT01610570

Software Mentioned

TopHat2
Partek Genomics Suite
Partek Genomic Suite
xCELLigence
MATLAB
Metamorph
Bowtie2

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Related Papers

Journal of Molecular and Genetic Medicine : an International Journal of Biomedical Research
Maya AgarwalGordon Li
Proceedings of the National Academy of Sciences of the United States of America
Saravana P SelvanathanJeffrey A Toretsky
© 2021 Meta ULC. All rights reserved